<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03638817</url>
  </required_header>
  <id_info>
    <org_study_id>RC31/16/8913</org_study_id>
    <secondary_id>2017-004489-88</secondary_id>
    <nct_id>NCT03638817</nct_id>
  </id_info>
  <brief_title>Perioperative Eltrombopag in Patients With Inherited Thrombocytopenia</brief_title>
  <acronym>ELPOT</acronym>
  <official_title>Evaluation of Perioperative Eltrombopag for the Management of Elective Surgery and Invasive Acts in Patients With Inherited Thrombocytopenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>French network for inherited hemorragic diseases</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Reference Centre for Platelet Pathologies</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Toulouse</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to estimate the response to eltrombopag based on platelet count
      increase above a safety level of 80 G/L and lack of requirement for pre-, per- and
      post-operative administration of platelet concentrates (PC) for performing elective invasive
      acts at mild or high bleeding risk,in selected patients with inherited thrombocytopenia (IT).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The hypothesis of the trial is that preoperative treatment by a thrombopoietin mimetic
      (eltrombopag) will be effective and safe and will avoid requirement of PC administration in a
      majority of IT patients Eltrombopag is a thrombopoietin mimetic available orally, not
      licenced for the treatment of IT. Preliminary data in short series of IT patients indicate
      that eltrombopag, at the doses used in primary immune thrombocytopenia, increases the
      platelet counts after 2-4 weeks of treatment and reduces spontaneous bleeding in a
      significant proportion of subjects. The tolerance of short-term treatment is good. The
      experience of eltrombopag for the management of perioperative thrombocytopenia in IT is
      anecdotic. Avoiding the administration of platelet concentrates in these patients, especially
      children, would represent a direct benefit by preventing adverse reactions to transfusion of
      blood products and human leukocyte antigen (HLA) immunisation.

      Eltrombopag will be prescribed after the inclusion visit at the standard dose of 50 mg/day
      with dose adjustment on the platelet count (+/- 25 mg) after 2 weeks, for a maximum of 4
      weeks before the invasive procedure. If the predefined safety level of platelet count
      required for the procedure is reached, the treatment will be discontinued and the patient
      operated without prophylactic administration of PC. In case of bleeding of undetermined cause
      per-and post-operatively, rescue PC will be given.

      Clinical and biological follow-up will be performed until the end-of-study visit, 4 weeks
      after the intake of the last tablet of eltrombopag.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 2, 2019</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Perioperative management by eltrombopag in inherited thrombocytopenia</measure>
    <time_frame>up to 4 weeks after completion of treatment</time_frame>
    <description>The response to Eltrombopag is a composite criteria including the level of platelet count 2 days before the procedure and the requirement of PC administration at any time in the study period. The &quot;study period&quot; is running from the start of treatment (inclusion visit) to 4 weeks after completion of treatment. A platelet count remaining below 80 G/L preoperatively, whether or not eltrombopag was taken, is a criterion of failure of treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>up to 4 weeks after completion of treatment</time_frame>
    <description>Adverse events and adverse reactions occurring at any time during the study period will be collected. Adverse events may be clinical and biological (especially liver function tests).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Excessive bleeding</measure>
    <time_frame>up to 4 weeks after completion of treatment</time_frame>
    <description>Excessive or unusual bleeding occurring at any time during the study period are major adverse events. An independent event adjudication committee (EAC) will review all bleeding events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vascular thrombosis</measure>
    <time_frame>up to 4 weeks after completion of treatment</time_frame>
    <description>Symptomatic thrombosis (venous or arterial) occurring at any time during the study period will be diagnosed by appropriate objective methods and reviewed by the EAC.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Doses of eltrombopag on-treatment</measure>
    <time_frame>2 and 4 weeks after the beginning of the treatment</time_frame>
    <description>The total doses of eltrombopag given in the preoperative period will be recorded, as the dose and duration of treatment required to obtained the safety level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet kinetics</measure>
    <time_frame>up to 4 weeks after completion of treatment</time_frame>
    <description>Serial blood sampling during the study period will be performed for measuring the rise of platelet count on-treatment and its decline after completion of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet size</measure>
    <time_frame>Inclusion and before the procedure</time_frame>
    <description>Mean platelet volume will be measured by flow cytometry.on blood samples obtained for platelet counts at inclusion, during hospitalisation and end-of study visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline of Serum Thrombopoietin</measure>
    <time_frame>Inclusion visit</time_frame>
    <description>Serum thrombopoietin will be measured once, at the inclusion visit.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Thrombocytopenia</condition>
  <arm_group>
    <arm_group_label>Eltrombopag</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eltrombopag</intervention_name>
    <description>Eltrombopag will be prescribed at doses recommended in primary immune thrombocytopenia (50, 25 or 75 mg), starting 4 weeks before the procedure and stopped 2 days before. PC will be administrated prophylactically if the platelet count is &lt; 80 G/L or per/post-operatively in case of bleeding of undetermined cause.
Antifibrinolytics will be authorized and low molecular weight heparin prescribed if indicated for the prophylaxis of postoperative venous thrombosis according to the standard dose and duration, , irrespective of the platelet count</description>
    <arm_group_label>Eltrombopag</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Symptomatic patients with bleeding history and chronic thrombocytopenia with strong
             presumption of constitutional origin on the basis of

               -  the identified mutation and/or

               -  a combination of the following criteria: familial antecedent with Mendelian
                  transmission, duration of thrombocytopenia, suggestive syndromic presentation,
                  and evidence against primary or secondary immune thrombocytopenia, especially
                  absence of immunologic markers and failure of previous conventional or
                  immunosuppressive therapies.

          -  Averaged platelet counts during the last five years below the safety level required
             for the procedure.

          -  Scheduled (&gt;4 weeks) surgery or invasive procedure with anticipated risk of bleeding:
             e.g. needle biopsy of solid organ (liver, kidneyâ€¦.etc.), interventional endoscopy,
             major surgeries, or surgery without possibility of mechanical control of haemostasis
             (e.g. tonsillectomy). Written informed consent of the patient or his (her) parents or
             tutors (patients &lt; 18 yrs).

        Patients included in the French national registry of rare platelet disorders

          -  Patient with social insurance coverage

        Exclusion Criteria:

          -  questionable constitutional origin;

          -  definite platelet dysfunction associated to thrombocytopenia (eg: gray platelet
             syndrome, NBEAL2 and related gene mutations, homozygous Bernard-Soulier Syndrome);

          -  thrombocytopenia with predisposition to hematologic malignancies (e.g; RUNX1, ETV6 or
             ANKRD26 gene mutations).

          -  amegakaryocytic thrombocytopenia resulting from mutations in the thrombopoietin (TPO)
             TPO-Mpl receptor, supposed, by definition, to be hardly responsive to receptor
             agonists.

          -  questionable requirement of prophylactic PC transfusions;

          -  procedure usually associated with platelet consumption requiring transfusions of PC
             (e.g.: cardiac surgery), making difficult the evaluation of success or failure;

          -  procedures at risk of bleeding with immediate vital or functional consequences (e.g.:
             intra cranial surgery);

          -  personal history of arterial or venous thromboembolic events or known familial
             thrombophilia;

          -  association with another acquired or constitutional hemorrhagic diathesis;

          -  chronic hepatitis, cirrhosis, with moderate to severe liver failure (Child-Pugh score
             â‰¥5);

          -  previous or concurrent myeloid malignancy, including myelodysplastic syndrome;

          -  alanine aminotransferase (ALT) or bilirubin levels 2 times the upper limit of normal
             (ULN);

          -  altered renal function (creatinin clearance &lt;30 ml/min);

          -  pregnancy (negative test required before inclusion in fertile women) or lactating
             women;

          -  refusal of safe contraception;

          -  ocular lenses opacity;

          -  hypersensitivity to eltrombopag or one of excipients;

          -  previous participation to the present study;

          -  current treatment with antiplatelet drugs, anticoagulants or direct acting antiviral
             agents approved for treatment of chronic hepatitis C infection;

          -  psychiatric, social or behavioral condition judged to be non-compatible with the
             respect of the protocol, including good observance of treatment and compliance to
             follow-up;

          -  adult protected by the law.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre SIE, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Toulouse</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pierre SIE, Prof.</last_name>
    <phone>561322289</phone>
    <phone_ext>33</phone_ext>
    <email>sie.p@chu-toulouse.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Angers Hospital</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe Beurrier</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bensancon Hospital</name>
      <address>
        <city>BesanÃ§on</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guillaume Mourey</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bordeaux Hospital</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mathieu FIORE</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Caen Hospital</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annie Borel-Derlon</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clermont-Ferrand Hospital</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guillaume Le Guenno</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dijon Hospital</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emmanuel De Maistre</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lille Hospital</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Camille Paris</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospices Civils Lyon</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandra Le Quellec, md</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Marseille Hospital</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie-Christine ALESSI</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Montpellier Hospital</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Biron-AndrÃ©ani</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nancy Hospital</name>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Birgit Frotscher</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nantes Hospital</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc FOUASSIER</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cochin Hospital</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mickaela Fontenay</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Europeen G Pompidou</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Darnige Luc</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kremlin Bicetre Hospital</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ValÃ©rie PROULLE</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Necker Hospital</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>StÃ©phane Blanche</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Robert DebrÃ© Hospital</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie-Christine Hurtaud</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Trousseau Hospital</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>RÃ©mi Favier</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Poitiers Hospital</name>
      <address>
        <city>Poitiers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurent MACCHI</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Reims Hospital</name>
      <address>
        <city>Reims</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe Nguyen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rennes Hospital</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sophie Bayart</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rouen Hospital</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Virginie Barbay</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Strasbourg Hospital</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dominique DESPREZ</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>university hospital Toulouse</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre SIE, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tours Hospital</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yves Gruel</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Pecci A, Gresele P, Klersy C, Savoia A, Noris P, Fierro T, Bozzi V, Mezzasoma AM, Melazzini F, Balduini CL. Eltrombopag for the treatment of the inherited thrombocytopenia deriving from MYH9 mutations. Blood. 2010 Dec 23;116(26):5832-7. doi: 10.1182/blood-2010-08-304725. Epub 2010 Sep 15.</citation>
    <PMID>20844233</PMID>
  </reference>
  <reference>
    <citation>Pecci A. Pathogenesis and management of inherited thrombocytopenias: rationale for the use of thrombopoietin-receptor agonists. Int J Hematol. 2013 Jul;98(1):34-47. doi: 10.1007/s12185-013-1351-7. Epub 2013 May 1. Review.</citation>
    <PMID>23636669</PMID>
  </reference>
  <reference>
    <citation>Pecci A, Barozzi S, d'Amico S, Balduini CL. Short-term eltrombopag for surgical preparation of a patient with inherited thrombocytopenia deriving from MYH9 mutation. Thromb Haemost. 2012 Jun;107(6):1188-9. doi: 10.1160/TH12-01-0005. Epub 2012 Mar 8.</citation>
    <PMID>22398565</PMID>
  </reference>
  <reference>
    <citation>Gerrits AJ, Leven EA, Frelinger AL 3rd, Brigstocke SL, Berny-Lang MA, Mitchell WB, Revel-Vilk S, Tamary H, Carmichael SL, Barnard MR, Michelson AD, Bussel JB. Effects of eltrombopag on platelet count and platelet activation in Wiskott-Aldrich syndrome/X-linked thrombocytopenia. Blood. 2015 Sep 10;126(11):1367-78. doi: 10.1182/blood-2014-09-602573. Epub 2015 Jul 29.</citation>
    <PMID>26224646</PMID>
  </reference>
  <reference>
    <citation>Favier R, Feriel J, Favier M, Denoyelle F, Martignetti JA. First successful use of eltrombopag before surgery in a child with MYH9-related thrombocytopenia. Pediatrics. 2013 Sep;132(3):e793-5. doi: 10.1542/peds.2012-3807. Epub 2013 Aug 12.</citation>
    <PMID>23940247</PMID>
  </reference>
  <reference>
    <citation>Fiore M, Saut N, Alessi MC, Viallard JF. Successful use of eltrombopag for surgical preparation in a patient with ANKRD26-related thrombocytopenia. Platelets. 2016 Dec;27(8):828-829. Epub 2016 Jun 8.</citation>
    <PMID>27276516</PMID>
  </reference>
  <reference>
    <citation>Zhang J, Liang Y, Ai Y, Xie J, Li Y, Zheng W. Thrombopoietin-receptor agonists for children with immune thrombocytopenia: a systematic review. Expert Opin Pharmacother. 2017 Oct;18(15):1543-1551. doi: 10.1080/14656566.2017.1373091. Epub 2017 Sep 4. Review.</citation>
    <PMID>28845713</PMID>
  </reference>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>June 29, 2018</study_first_submitted>
  <study_first_submitted_qc>August 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 20, 2018</study_first_posted>
  <last_update_submitted>August 19, 2019</last_update_submitted>
  <last_update_submitted_qc>August 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Inherited thrombocytopenias (IT)</keyword>
  <keyword>Platelet concentrates (PC)</keyword>
  <keyword>Eltrombopag</keyword>
  <keyword>Surgery</keyword>
  <keyword>Invasive acts</keyword>
  <keyword>Perioperative</keyword>
  <keyword>Rare disease</keyword>
  <keyword>Thrombopoietin mimetic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombocytopenia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

